Labcorp will acquire select BioReference Health assets from OPKO Health for $722 million, including clinical, urology, and women’s health labs, 80+ patient service centers, and the FDA-approved 4Kscore prostate cancer test.
Joel Braunstein, MD, CEO of C2N Diagnostics, received the Nimoy-Knight Live Long & Prosper Tribute Award after FDA clearance of PrecivityAD2, the first Alzheimer’s blood test for adults with cognitive symptoms as young as 40.
Labcorp has acquired MLM Medical Labs, expanding its central laboratory network to four continents and strengthening biomarker and specialty testing capabilities for clinical trials, according to a company announcement.
Quest Diagnostics will launch an FDA-cleared Roche pTau217 Alzheimer’s blood test and a new multi-biomarker LDT, expanding its AD-Detect portfolio for improved diagnostic accuracy in late 2026.
Read More
Labcorp will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to aid in identifying amyloid pathology linked to Alzheimer’s in patients 55 and older with cognitive decline.
Read More
Craif Inc has raised $34 million in Series D funding to support a US launch of its urine-based cancer test, expand San Diego lab operations, and advance a pancreatic cancer study and regulatory filing in Japan.
Read More
The strategic alliance will leverage de-identified laboratory data to support quality improvement across 1,526 community health centers and includes a leadership exchange program for chief medical officers.
Read More
Century Health and GI Partners of Illinois have partnered to create a real-world data ecosystem for IBD and MASH, leveraging AI to extract clinical insights from lab data, pathology reports, and imaging to support research and pharmaceutical innovation.
Read More
Cerenome’s CNSide Diagnostics has selected XiFin to provide automated revenue cycle management for its cerebrospinal fluid assay platform, aiming to support increased test volumes and streamline billing as payer coverage expands.
Read More
Epredia will incorporate Leeds NHS Trust’s TANGO quality control technology into pathology slides, aiming to enhance staining consistency for digital pathology and AI diagnostics. Integration is set to begin in late 2026.
Read More
BRAINBox Solutions has secured financing from Pivotal Capital Partners and New Horizon Bank to advance its point-of-care and lab-based concussion diagnostic devices for traumatic brain injury.
Read More
VolitionRx reports progress in licensing talks with over 12 diagnostic firms and advances in clinical and veterinary assays, including a reimbursement submission for its Nu.Q Lung Cancer test and a feline lymphoma study milestone.
Read More
VolitionRx reports its finger-prick lateral flow prototype for sepsis shows strong correlation with its automated Nu.Q NETs assay, supporting point-of-care nucleosome testing for critically ill patients.
Read More
Astorg has completed its acquisition of Thermo Fisher’s global microbiology business, establishing an independent diagnostics company. Dirk Bontridder has been named CEO.
Read More
QIAGEN has received FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, enabling detection of 20 pathogens and 10 antimicrobial resistance markers from positive blood cultures in about one hour.
Read More
bioMérieux hosted a panel on diagnostic delays and received seven 2026 IMV ServiceTrak awards for system performance and customer support at the ADLM Annual Conference & Clinical Lab Expo.
Read More
Personalis has received UKCA marking for its NeXT Personal Dx test, enabling clinical use of its minimal residual disease detection technology across Great Britain, the company announced.
Read More
Concert has issued a coverage policy deeming the EsoGuard Esophageal DNA Test medically necessary for eligible patients, with multiple client health plans now adopting the policy.
Read More